Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis

被引：2
|
作者：
Kamat, Shweta [1 ]
Patel, Jay [1 ]
Brown, Britny R. [1 ]
Vyas, Ami [1 ]
机构：
[1] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, 7 Greenhouse Rd, Kingston, RI 02881 USA
来源：
CANCER INVESTIGATION | 2022年 / 40卷 / 09期
基金：
美国国家卫生研究院;
关键词：
Nivolumab; ipilimumab; immune checkpoint inhibitors; adverse events; meta-analysis; STAGE IV MELANOMA; PREDICTIVE BIOMARKERS; ADJUVANT NIVOLUMAB; DOUBLE-BLIND; IMMUNOTHERAPY;
D O I：
10.1080/07357907.2022.2108827
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).
引用
收藏
页码：777 / 788
页数：12
相关论文
共 50 条
  • [21] The efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis
    Zhu, Yuqing
    Cheng, Hui
    Zhong, Minhong
    Hu, Yijie
    Li, Qiushuang
    Gao, Xiangfu
    Liu, Shan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2021, 17 (07) : 1679 - +
  • [22] Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
    Xu, Hang
    Tan, Ping
    Ai, Jianzhong
    Zhang, Shiyu
    Zheng, Xiaonan
    Liao, Xinyang
    Yang, Lu
    Wei, Qiang
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [23] Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab plus Ipilimumab
    Friedman, Claire F.
    Clark, Varina
    Raikhel, Andrew V.
    Barz, Tim
    Shoushtari, Alexander N.
    Momtaz, Parisa
    Callahan, Margaret K.
    Wolchok, Jedd D.
    Chapman, Paul B.
    Hellmann, Matthew D.
    Postow, Michael A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (04):
  • [24] A pooled meta-analysis of salvage nivolumab/ipilimumab (N plus I) after nivolumab (N) in patients with advanced renal cell carcinoma (RCC)
    Mckay, R. R.
    Xie, W.
    Leucht, K.
    Jegede, O.
    Braun, D. A.
    Atkins, M. B.
    Grimm, M-O.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1017 - S1018
  • [25] BUDESONIDE VS. MESALAMINE IN MICROSCOPIC COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF EFFICACY AND ADVERSE EVENTS
    Malik, Adnan
    Goyal, Hemant
    Perisetti, Abhilash
    Nadeem, Mahum
    Gajendran, Mahesh
    Ali, Aman
    Tharian, Benjamin
    Enders, Gregory
    GASTROENTEROLOGY, 2021, 160 (06) : S277 - S277
  • [26] Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
    Maloney, Anna K.
    Giobbie-Hurder, Anita
    Katukota, Nikita
    Fogarasi, Miklos C.
    Ott, Patrick A.
    Hodi, F. Stephen
    Sussman, Tamara A.
    Silk, Ann W.
    Haq, Rizwan
    Liu, David
    Insco, Megan
    Buchbinder, Elizabeth, I
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08)
  • [27] Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis
    Zhang, Ya-Jun
    Tian, Qian-Yu
    Wang, Cai-E.
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [28] Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis
    Najah, Qasi
    Almosilhy, Nereen A.
    Ghanm, Thoria Ibrahim Essa
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2025, 81 (02) : 269 - 278
  • [29] CARDIOVASCULAR ADVERSE EVENTS ASSOCIATED WITH NIVOLUMAB VERSUS STANDARD CHEMOTHERAPY IN PATIENTS WITH CANCER. A META-ANALYSIS OF RAMDOMIZED CONTROL TRIALS
    Calderon, Eder Cativo
    Guevara, Nehemias
    Coreas, Noemy
    Loyo, Persio Lopez
    Cativo, Diana P.
    Manohar, Hasitha
    Gaddam, Anurag
    Atlas, Steven
    Rosendorff, Clive
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3315 - 3315
  • [30] Evidence from a meta-analysis: is nivolumab neurotoxic in cancer patients?
    Kong, Xiangyi
    Kong, Yanguo
    ONCOTARGETS AND THERAPY, 2017, 10 : 1335 - 1344
12345